Caitong International Asset Management Co. Ltd Trims Stake in Sarepta Therapeutics, Inc. $SRPT

Caitong International Asset Management Co. Ltd reduced its position in Sarepta Therapeutics, Inc. (NASDAQ:SRPT) by 16.0% during the second quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 6,358 shares of the biotechnology company’s stock after selling 1,209 shares during the quarter. Caitong International Asset Management Co. Ltd’s holdings in Sarepta Therapeutics were worth $109,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. Ancora Advisors LLC raised its position in Sarepta Therapeutics by 150.0% in the 1st quarter. Ancora Advisors LLC now owns 500 shares of the biotechnology company’s stock worth $32,000 after purchasing an additional 300 shares during the period. Pandora Wealth Inc. purchased a new stake in Sarepta Therapeutics in the 1st quarter worth about $45,000. Brooklyn Investment Group raised its position in Sarepta Therapeutics by 450.4% in the 1st quarter. Brooklyn Investment Group now owns 721 shares of the biotechnology company’s stock worth $46,000 after purchasing an additional 590 shares during the period. Banque Transatlantique SA purchased a new stake in Sarepta Therapeutics in the 1st quarter worth about $44,000. Finally, Hurley Capital LLC raised its position in Sarepta Therapeutics by 139.2% in the 1st quarter. Hurley Capital LLC now owns 1,435 shares of the biotechnology company’s stock worth $92,000 after purchasing an additional 835 shares during the period. 86.68% of the stock is owned by hedge funds and other institutional investors.

Sarepta Therapeutics Price Performance

NASDAQ SRPT opened at $22.81 on Friday. The company has a debt-to-equity ratio of 0.84, a quick ratio of 1.81 and a current ratio of 2.89. The firm’s 50 day moving average price is $19.90 and its 200-day moving average price is $28.31. Sarepta Therapeutics, Inc. has a 52-week low of $10.41 and a 52-week high of $138.81. The company has a market cap of $2.23 billion, a PE ratio of -26.22 and a beta of 0.51.

Sarepta Therapeutics (NASDAQ:SRPT) last released its quarterly earnings data on Wednesday, August 6th. The biotechnology company reported $2.02 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.89 by $1.13. Sarepta Therapeutics had a negative net margin of 2.34% and a negative return on equity of 1.03%. The firm had revenue of $611.09 million for the quarter, compared to the consensus estimate of $530.66 million. During the same period last year, the firm earned $0.07 earnings per share. The company’s quarterly revenue was up 68.4% on a year-over-year basis. Sell-side analysts forecast that Sarepta Therapeutics, Inc. will post 2.67 EPS for the current fiscal year.

Wall Street Analyst Weigh In

A number of research firms recently weighed in on SRPT. Sanford C. Bernstein began coverage on shares of Sarepta Therapeutics in a research report on Tuesday, July 29th. They issued a “market perform” rating and a $13.00 price objective on the stock. The Goldman Sachs Group raised their target price on shares of Sarepta Therapeutics to $19.00 and gave the stock a “neutral” rating in a research report on Thursday, August 7th. Royal Bank Of Canada raised their target price on shares of Sarepta Therapeutics from $14.00 to $16.00 and gave the stock a “sector perform” rating in a research report on Wednesday, October 8th. Deutsche Bank Aktiengesellschaft raised their target price on shares of Sarepta Therapeutics to $12.00 and gave the stock a “sell” rating in a research report on Friday, August 15th. Finally, JPMorgan Chase & Co. raised shares of Sarepta Therapeutics from an “underweight” rating to a “neutral” rating and set a $24.00 target price on the stock in a research report on Tuesday, July 29th. Eight analysts have rated the stock with a Buy rating, fourteen have issued a Hold rating and seven have issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock has an average rating of “Hold” and a consensus price target of $34.46.

About Sarepta Therapeutics

Sarepta Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene.